ADORA2A and neoplasm: Small-molecule inhibition of CD73 or A2aR can enhance the anti-tumor effect of TME, sensitization immunotherapy, and immunotherapy, providing a novel, efficient, and promising immunotherapy combination strategy for PDAC.